Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Correlation between specific serum IgE and exhaled NO levels at low and high inhaled corticosteroid use in allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Returning asthma symptoms correlate with free IgE upon omalizumab cessation Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016
Epidemiology of serum IgE in children with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 373s Year: 2001
Serum leptin levels in asthmatic children treated with inhaled corticosteroid Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Influence of glucocorticosteroids on free and bound metenkefaline levels in serum of children with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 220s Year: 2002
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016
Effect of montelukast administration on serum IL-5 and total IgE levels in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
Serum level of specific IgG antibody for aspergillus and its association with severity of asthma in asthmatic children Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012
Possible impact of serum IgE variability on dose calculation of omalizumab (anti-IgE) Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004